Transplantation Proceedings
Volume 35, Issue 8 , Pages 2873-2877 , December 2003

Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients

  • N.R Florea

      Affiliations

    • Department of Pharmacy Practice, Loma Linda University School of Pharmacy (N.R.F.), Loma Linda, California, USA
    • ,
  • B Capitano

      Affiliations

    • Department of Pharmacy and Therapeutics, Department of Medicine, University of Pittsburgh (B.C.), Pittsburgh, Pennsylvania, USA
    • ,
  • C.H Nightingale

      Affiliations

    • Center for Anti-Infective Research and Development (C.H.N., D.P.N.), Hartford, Connecticut, USA
    • Division of Research Administration (C.H.N.), Hartford, Connecticut, USA
    • ,
  • D Hull

      Affiliations

    • Department of Transplantation (D.H.), Hartford, Connecticut, USA
    • ,
  • G.J Leitz

      Affiliations

    • Ortho-Biotech (G.J.L.), Bridgewater, New Jersey, USA
    • ,
  • D.P Nicolau

      Affiliations

    • Center for Anti-Infective Research and Development (C.H.N., D.P.N.), Hartford, Connecticut, USA
    • Division of Infectious Diseases (D.P.N.), Hartford Hospital, Hartford, Connecticut, USA
    • Corresponding Author InformationAddress reprint requests to David P. Nicolau, Pharm. D. FCCP, Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102D, USA

References 

  1. Nampoory MR, Khan ZU, Johny KV, et al.  Invasive fungal infections in renal transplant recipients. J Infect. 1996;33:95
  2. Abbott KC, Hypolite I, Poropatich RK, et al.  Hospitalizations for fungal infections after renal transplantation in the United States. Trans Infec Dis. 2001;3:203
  3. Hibberd PL, Rubin RH. Renal transplantation and related infections. Semin Respir Infect. 1993;8:216
  4. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 1994;330:263
  5. Myoken Y, Sugata T, Kyo T, et al.  Itraconazole prophylaxis for invasive gingival aspergillosis in neutropenic patients with acute leukemia. J Periodontol. 2002;73:33
  6. Hay RJ, Clayton YM. Treatment of chronic dermatophytosis and chronic oral candidosis with itraconazole. Rev Infect Dis. 1987;9(suppl 1):114
  7. Galimberti RL, Flores V, Gonzalez Ramos MC, et al.  Cutaneous ulcers due to Candida albicans in an immunocompromised patient—response to therapy with itraconazole. Clin Exp Dermatol. 1989;14:295
  8. Lindholm A, Kahan BD. Influence of cyclosproien pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmcol Ther. 1993;54:205
  9. Schroeder TJ, Hariharin S, First MR. Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients. Transplant Proc. 1994;26:2787
  10. Levy GA. Relationship of pharmacokinetics to clinical outcomes. Transplant Proc. 1999;31:1654
  11. Lindholm A. Cyclosporine A (clinical experience and therapeutic drug monitoring). Ther Drug Monit. 1995;17:631
  12. Kramer MR, Merin G, Rudis E, et al.  Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). Transplant Proc. 1997;29:2657
  13. McLachlan AJ, Trett SE. Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. Ther Drug Monit. 1998;20:390
  14. Product Information: Sporanox® itraconazole oral solution, Ortho Biotech, Raritan, New Jersey, 2002
  15. Woestenborghs R, Lorreyne W, Heykants J. Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J Chromatogr. 1997;413:332
  16. Campana C, Regazzi MB, Buggia I, et al.  Clinically significant drug interactions with cyclosporine. An update. Clin Pharmacokinet. 1997;32:173

☆ Supported by a grant from Ortho Biotech, Raritan, New Jersey.

PII: S0041-1345(03)01204-1

doi: 10.1016/j.transproceed.2003.10.058

Transplantation Proceedings
Volume 35, Issue 8 , Pages 2873-2877 , December 2003

Article Tools